Ping Ping Tong

US Patent:

20100278905, Nov 4, 2010

Filed:

Apr 29, 2010

Appl. No.:

12/770174

Inventors:

Nathaniel Catron - Vernon Hills IL, US
Michael G. Fickes - Evanston IL, US
Cristina M. Fischer - Wadsworth IL, US
Anthony R. Haight - Wadsworth IL, US
Katherine Heemstra - Chicago IL, US
Yeshwant D. Sanzgiri - Gurnee IL, US
Eric A. Schmitt - Libertyville IL, US
Ping Tong - Libertyville IL, US
Geoff G. Z. Zhang - Libertyville IL, US
Deliang Zhou - Vernon Hills IL, US

International Classification:

A61K 31/5377
A61K 9/127
A61K 9/66
A61P 35/00
A61P 35/02

US Classification:

424450, 5142358, 424455

Abstract:

An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

US Patent:

20100278921, Nov 4, 2010

Filed:

Apr 29, 2010

Appl. No.:

12/770205

Inventors:

Cristina M. Fischer - Wadsworth IL, US
Rajeev Gokhale - Libertyville IL, US
Katherine Heemstra - Chicago IL, US
David Hill - Gurnee IL, US
Kennan Marsh - Lake Forest IL, US
Eric A. Schmitt - Libertyville IL, US
Yi Shi - Libertyville IL, US
Ping Tong - Libertyville IL, US
Deliang Zhou - Vernon Hills IL, US

International Classification:

A61K 31/5377
A61K 9/14
A61P 35/00

US Classification:

424489, 5142358

Abstract:

An orally deliverable pharmaceutical composition comprises (a) a pharmaceutically acceptable acid addition salt of ABT-263 in solid particulate form, and (b) a plurality of pharmaceutically acceptable excipients including at least a solid diluent and a solid disintegrant; wherein the salt is formed from more than one equivalent of acid per equivalent of ABT-263. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

US Patent:

20100280031, Nov 4, 2010

Filed:

Apr 29, 2010

Appl. No.:

12/770122

Inventors:

Paul David - Lindenhurst IL, US
Michael G. Fickes - Evanston IL, US
Cristina M. Fischer - Wadsworth IL, US
Anthony R. Haight - Wadsworth IL, US
Katherine Heemstra - Chicago IL, US
Kennan Marsh - Lake Forest IL, US
Peter Mayer - Libertyville IL, US
Vitaly Rubin - Niles IL, US
Yeshwant D. Sanzgiri - Gurnee IL, US
Eric A. Schmitt - Libertyville IL, US
Ping Tong - Libertyville IL, US
Deliang Zhou - Vernon Hills IL, US

International Classification:

A61K 31/5377
A61K 31/4965
A61P 35/00
A61P 35/02

US Classification:

5142358, 51425503

Abstract:

An orally deliverable pharmaceutical composition comprises a drug-carrier system having a Bcl-2 family protein inhibitory compound, e.g., ABT-263, in solution in a substantially non-aqueous carrier that comprises at least one phospholipid and a pharmaceutically acceptable solubilizing agent. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

US Patent:

20100297194, Nov 25, 2010

Filed:

Apr 29, 2010

Appl. No.:

12/770299

Inventors:

Nathaniel Catron - Vernon Hills IL, US
Michael G. Fickes - Evanston IL, US
Cristina M. Fischer - Wadsworth IL, US
Rajeev Gokhale - Libertyville IL, US
Anthony R. Haight - Wadsworth IL, US
Katherine Heemstra - Chicago IL, US
David Hill - Gurnee IL, US
Martin Knobloch - Neuhofen, DE
Drazen Kostelac - Roemerberg, DE
Justin S. Lafountaine - Chicago IL, US
Yanxia Li - Grayslake IL, US
Bernd Liepold - Dossenheim, DE
Kennan Marsh - Lake Forest IL, US
Jonathan M. Miller - Lindenhurst IL, US
Claudia Packhaeuser - Munich, DE
Yeshwant D. Sanzgiri - Gurnee IL, US
Eric A. Schmitt - Libertyville IL, US
Yi Shi - Libertyville IL, US
Norbert Steiger - Lingenfeld, DE
Ping Tong - Libertyville IL, US
Huailiang Wu - Long Grove IL, US
Geoff G.Z. Zhang - Libertyville IL, US
Deliang Zhou - Vernon Hills IL, US

International Classification:

A61K 31/5377
A61K 33/04
A61K 9/14
A61P 35/00

US Classification:

424400, 5142358, 424711, 424709

Abstract:

An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier; wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

US Patent:

20100311751, Dec 9, 2010

Filed:

Jun 8, 2010

Appl. No.:

12/796061

Inventors:

Eric A. Schmitt - Libertyville IL, US
Ping Tong - Libertyville IL, US
Katherine Heemstra - Chicago IL, US
Cristina M. Fischer - Wadsworth IL, US
Huailiang Wu - Long Grove IL, US
Jonathan Mark Miller - Lindenhurst IL, US
Yanxia Li - Grayslake IL, US
Justin S. Lafountaine - Chicago IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 31/5377
A61P 35/00

US Classification:

5142358

Abstract:

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

US Patent:

20110159085, Jun 30, 2011

Filed:

Dec 21, 2010

Appl. No.:

12/974154

Inventors:

Ping Tong - Libertyville IL, US
Deliang Zhou - Vernon Hills IL, US
Geoff G.Z. Zhang - Vernon Hills IL, US
Katherine R. Heemstra - Chicago IL, US
Cristina M. Fischer - Wadsworth IL, US
Nathaniel D. Catron - Vernon Hills IL, US
Eric A. Schmitt - Libertyville IL, US
Yeshwant D. Sanzgiri - Gurnee IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 9/48
A61P 35/00
A61K 31/5377
A61J 3/07

US Classification:

424452, 5142358, 264 4

Abstract:

A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

US Patent:

20120108590, May 3, 2012

Filed:

Oct 5, 2011

Appl. No.:

13/253727

Inventors:

Esther Birtalan - Karlsruhe, DE
Peter Hoelig - Waechtersbach, DE
David J. Lindley - Antioch IL, US
Yeshwant D. Sanzgiri - Gurnee IL, US
Ping Tong - Libertyville IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 31/496
A61P 35/02
A61P 37/00
A61K 31/5377
A61P 35/00

US Classification:

5142345, 51425309, 51425211, 51425304

Abstract:

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula I, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer or an immune or autoimmune disease.

US Patent:

20120277210, Nov 1, 2012

Filed:

Oct 27, 2011

Appl. No.:

13/282773

Inventors:

Nathaniel Catron - Vernon Hills IL, US
David Lindley - Antioch IL, US
Jonathan M. Miller - Lindenhurst IL, US
Eric A. Schmitt - Libertyville IL, US
Ping Tong - Libertyville IL, US

Assignee:

ABBOTT LABORATORIES - Abbott Park IL

International Classification:

A61K 31/496
A61K 31/517
A61P 37/00
A61P 35/00
A61P 35/02
A61K 31/5377
A61K 31/541

US Classification:

51421021, 51425304, 5142345, 51425211, 51425409, 5142352, 51425217, 5142282

Abstract:

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.